‹ All Posts
Prameela Balakkala

7 mins ago · SEBI Registration INH000016074

Glenmark Pharma Launches Inlyta Generic in the US

GLENMARK Glenmark Pharmaceuticals has launched the authorized generic version of Inlyta (Axitinib) tablets in 1 mg and 5 mg strengths in the United States. Key Business Highlights - Product: Axitinib tablets (authorized generic of Inlyta). - Strengths: 1 mg and 5 mg. - Market: United States. - Annual US Market Sales: Approximately $538.4 million. - Therapeutic Segment: Oncology. - The launch expands Glenmark's presence in the US specialty generics market. Business Significance - Provides an opportunity to participate in a sizeable oncology drug market. - Strengthens Glenmark's US product portfolio. - Could support incremental revenue growth, depending on market share and pricing. Risk Factors - Competition from other generic manufacturers. - Pricing pressure in the US pharmaceutical market. - Market share and prescription uptake may differ from expectations. - Regulatory and supply-chain requirements. Market Takeaway The launch is a positive product development for Glenmark, providing access to a US market with reported annual sales of $538.4 million. Actual revenue contribution will depend on market penetration, competition and pricing. Disclaimer: For educational purposes only. Not investment advice or a recommendation to buy or sell any security.

#PersonalFinance#IndexStrategies#TechnicalViews
1 like